BOC Sciences offers an end-to-end glycan-conjugate vaccine development service. Their integrated team of glycobiology, immunology, and bioprocess development experts can assist with designing and synthesizing glycans, conjugation to selected carrier proteins, and formulating vaccines for improved safety and efficacy. Analytical capabilities and GMP process development enable our team to support our partners through the discovery stage and into preclinical evaluation. The team of scientific and regulatory experts can work with you to design, develop, and deliver your next-generation glycan-based vaccine.
Developing glycan-conjugate vaccines involves unique scientific and technical hurdles. Our solutions address:
Complex Glycan Synthesis & Conjugation: Overcoming difficulties in reproducible glycan design, functionalization, and site-specific conjugation to carrier proteins.
Immunogenicity Optimization: Ensuring strong and targeted immune responses through strategic glycan-protein conjugate selection.
Process Scalability: Streamlining laboratory protocols into GMP-compliant manufacturing processes.
Analytical Complexity: Tackling the challenges of structural characterization, stability testing, and quality control for carbohydrate-based vaccines.
We provide tailored carbohydrate synthesis and modification to meet the unique structural and functional needs of glycan-based vaccine projects.
Our team applies advanced conjugation techniques to ensure stable and immunogenic glycan-protein constructs.
We engineer and optimize carrier proteins to maximize immune stimulation and minimize adverse effects.
We offer comprehensive analytical services to ensure vaccine quality, consistency, and regulatory compliance.
Our preclinical expertise accelerates the evaluation of vaccine candidates.
We help streamline the regulatory pathway with clear, compliant documentation and expert guidance.
Partnering with us for glycan-conjugate vaccine development offers unique benefits that accelerate innovation and reduce risk.
End-to-End Expertise: From glycan design to preclinical evaluation, we provide comprehensive support across the vaccine development process.
Cutting-Edge Technology: Advanced glycan synthesis platforms, site-specific conjugation, and state-of-the-art analytical tools.
Scalability & Flexibility: Solutions adaptable from small-scale research batches to large-scale GMP production.
Collaborative Partnership: Dedicated scientific and project management teams for transparent communication and reliable delivery.
Our glycan-conjugate vaccine development services have broad applications across multiple therapeutic and preventive areas:
We follow a structured and transparent workflow to ensure efficient progress in glycan-conjugate vaccine development.
Initial assessment of project goals, antigen targets, and regulatory considerations to tailor a customized development plan.
Laboratory synthesis of glycans, followed by optimized conjugation with selected carrier proteins.
Comprehensive quality control, including glycan profiling, conjugate stability, and immunogenicity verification.
In vitro and in vivo testing for efficacy, safety, and immune response optimization.
Process development for scalable production aligned with GMP requirements.
Preparation of compliant data packages and regulatory guidance to support preclinical research and development.
A glycan-conjugate vaccine links carbohydrate antigens (glycans) to carrier proteins, improving immunogenicity and generating stronger, long-lasting immune responses.
Many pathogens use polysaccharides on their surface to evade the immune system. Conjugation to proteins makes these antigens more recognizable, enabling effective and protective immune responses.
Yes. We provide scalable process development and technology transfer, bridging research-grade work to GMP-compliant production.
Absolutely. We tailor glycan synthesis, conjugation strategies, and carrier protein engineering to fit each client's unique therapeutic or preventive goals.
Accelerate your innovation in glycan-conjugate vaccine development with our end-to-end expertise. Whether you are advancing vaccines for infectious diseases, oncology, or rare disorders, our team delivers the precision, scalability, and regulatory readiness you need. We also provide access to a diverse portfolio of well-characterized glycans, including but not limited to: sialic acids, Lewis antigens, blood group antigens, mannose-rich glycans, and tumor-associated carbohydrate antigens (TACAs).
Contact us today to discuss your project and discover how our glycan-conjugate solutions can transform your vaccine development pipeline.
